Roche freezes Germany investments
Swiss drugmaker Roche has suspended future investments in Germany citing damaging healthcare cost-cutting policies. The company joins Eli Lilly in raising concerns over recent statutory health insurance legislation.
Xurve View
Insights:
Xurve View
ROCHE HOLDING AG-BR put future capital projects in Germany on hold over statutory health insurance cost-cutting policies, the drugmaker's local chief said Monday morning. The freeze follows a similar move by ELI LILLY & CO earlier this year, compounding pharmaceutical sector friction with policy makers. Investor sentiment toward European life sciences infrastructure faces mounting pressure as drugmakers reassess regional stability.
